Alexander Schubert
InvestorPartner at SciFounders
San Francisco Bay Area
Writes $400K – $1M checks · typically $1.5M
About
Alexander Schubert is an early-stage deep tech investor focused on biotech and science-driven startups. He writes extensively about founder-led biotech, how research-intensive companies can be built with limited funding, and where AI can be applied across the biopharma value chain — from drug discovery to the document-heavy operational backbone of late-stage clinical development. His fund invests in a small fraction of the companies it evaluates, concentrating on early-stage deep tech. He is associated with SciFounders and works alongside teammate Matt Krisiloff.
Contact· published on Alexander's own website
Invests in
AI & Machine LearningBiotechDeep TechHardwareHealthtechMedical Devices
Beyond investing
- Communities
- Works alongside teammate Matt Krisiloff at SciFounders.
From Alexander's own website — common ground for a warm intro.
Experience
- SciFoundersPartner and Co-Foundercurrent2021 — presentSan Francisco Bay Area
- GenentechIndependent Researcher2018 — 2021
- MRC Laboratory of Molecular Biology (LMB)PhD Researcher2014 — 2018Greater Cambridge Area
Skills & more
Languages Deutsch · Englisch
- Doctor of Philosophy — University of Cambridge
From Alexander's professional profile.
Writing
All posts ↗Alexander Schubert writes about AI and biotech opportunities, covering LLM automation of late-stage clinical and regulatory workflows and computational venom mining for drug discovery, as well as how deep tech VCs evaluate early-stage startups.
The author argues that late-stage clinical development workflows like regulatory affairs, pharmacovigilance, clinical trial programming, and medical writing are underexplored, document-heavy areas well-suited for LLM automation despite high stakes and difficult sales.
The author contends that animal toxins are a vast untapped drug-discovery resource and that next-gen sequencing, LLMs, and molecular docking now make large-scale venom mining feasible and cost-effective.
Drawing on notes from ~500 startups, the author outlines seven factors deep tech VCs evaluate, including differentiation, opportunity size, commercialization risk, founding team, communication, and science.
Colleagues at SciFounders
Frequently asked questions
- Who is Alexander Schubert?
- Alexander Schubert is an early-stage deep tech investor focused on biotech and science-driven startups. He writes extensively about founder-led biotech, how research-intensive companies can be built with limited funding, and where AI can be applied across the biopharma value chain — from drug discovery to the document-heavy operational backbone of late-stage clinical development. His fund invests in a small fraction of the companies it evaluates, concentrating on early-stage deep tech. He is associated with SciFounders and works alongside teammate Matt Krisiloff.
- Where does Alexander Schubert work?
- Alexander Schubert is Partner at SciFounders.
- What does Alexander Schubert invest in?
- Alexander Schubert invests in AI & Machine Learning, Biotech, Deep Tech, Hardware, Healthtech, Medical Devices.
- What check size does Alexander Schubert write?
- Alexander Schubert typically writes checks of $400K – $1M.
- Where did Alexander Schubert go to school?
- Alexander Schubert studied at University of Cambridge (Doctor of Philosophy (PhD), Molecular Biology).
- What has Alexander Schubert written?
- Alexander Schubert has 3 tracked posts on alexschubert.xyz, including "Is the Boring Backbone of Biopharma the Next Big AI Opportunity?", "Into the venom mines", "Why we have to pass on startups".
Same school
Also attended University of Cambridge893
.png)
+ 887 more
Shared employers
Also worked at Genentech101
+ 95 more
